Advertisement
U.S. markets open in 3 hours 32 minutes

Avalo Therapeutics, Inc. (AVTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.4100-0.1400 (-3.08%)
At close: 04:00PM EST
4.3700 -0.04 (-0.91%)
Pre-Market: 04:17AM EST

Avalo Therapeutics, Inc.

540 Gaither Road
Suite 400
Rockville, MD 20850
United States
410 522 8707
https://www.avalotx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Garry A. Neil M.D.Chairman of the Board, President & CEO601.9kN/A1954
Mr. Christopher Ryan SullivanCFO & Head of Investor relations466.94kN/A1984
Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory BoardN/AN/A1939
Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory BoardN/AN/A1965
Dr. Lisa Hegg Ph.D.Senior Vice President of Program Management, Corporate Infrastructure & Clinical OperationsN/AN/AN/A
Ms. Colleen MatkowskiSenior Vice President of Global Regulatory Affairs & Quality AssuranceN/AN/AN/A
Dr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Corporate Governance

Avalo Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.